Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063215 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
A Phase 1 study, sponsored by Hope Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04063215 is a Phase 1 study that has completed, run by Hope Biosciences. The registered enrollment target is 24 participants.
The verdict
NCT04063215, a Phase 1 study, has completed, sponsored by Hope Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury in adults.
Interventions
- BIOLOGICAL HB-adMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04063215
The ClinicalTrials.gov registry entry for NCT04063215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HB-adMSCs is the first listed.
NCT04063215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04063215 about?
NCT04063215 is a clinical study titled "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy". This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury in adults.
What is the current status of trial NCT04063215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-01-01. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT04063215?
The interventions under investigation include: HB-adMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT04063215?
This trial is sponsored by Hope Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.